Engineered In Vitro Disease Models

Kambez H. Benam(Harvard University), Stephanie Dauth(Harvard University), Bryan Hassell(Harvard University), Anna Herland(Harvard University), Abhishek Jain(Harvard University), Kyung‐Jin Jang(Harvard University), Katia Karalis(Boston Children's Hospital), Hyun Jung Kim(Harvard University), Luke A. MacQueen(Harvard University), Roza Mahmoodian(Harvard University), Samira Musah(Harvard University), Yu‐suke Torisawa(Harvard University), Andries D. van der Meer(Harvard University), Rémi Villenave(Harvard University), Moran Yadid(Harvard University), Kevin Kit Parker(Harvard University), Donald E. Ingber(Boston Children's Hospital)
Annual Review of Pathology Mechanisms of Disease
January 24, 2015
Cited by 539

Abstract

The ultimate goal of most biomedical research is to gain greater insight into mechanisms of human disease or to develop new and improved therapies or diagnostics. Although great advances have been made in terms of developing disease models in animals, such as transgenic mice, many of these models fail to faithfully recapitulate the human condition. In addition, it is difficult to identify critical cellular and molecular contributors to disease or to vary them independently in whole-animal models. This challenge has attracted the interest of engineers, who have begun to collaborate with biologists to leverage recent advances in tissue engineering and microfabrication to develop novel in vitro models of disease. As these models are synthetic systems, specific molecular factors and individual cell types, including parenchymal cells, vascular cells, and immune cells, can be varied independently while simultaneously measuring system-level responses in real time. In this article, we provide some examples of these efforts, including engineered models of diseases of the heart, lung, intestine, liver, kidney, cartilage, skin and vascular, endocrine, musculoskeletal, and nervous systems, as well as models of infectious diseases and cancer. We also describe how engineered in vitro models can be combined with human inducible pluripotent stem cells to enable new insights into a broad variety of disease mechanisms, as well as provide a test bed for screening new therapies.


Related Papers

No related papers found

Powered by citation graph analysis